Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamsulosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 10/20 | 0.98 |
| ▸ | ADRA1D known ✓ | P25100 | 9/20 | 0.98 |
| ▸ | ADRA1B known ✓ | P35368 | 9/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.98 |
| ▸ | HTR1A | P08908 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | DRD2 | P14416 | 2/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.98 |
| ▸ | HTR2A | P28223 | 2/20 | 0.98 |
| ▸ | DRD3 | P35462 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | HTR7 | P34969 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamsulosin SCHEMBL29641643 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29823016 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL3397438 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL2319987 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29625170 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL1560198 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL23428 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL9300408 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL356385 | 0.99 | ADRA1A (0.96) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL11815414 | 0.99 | ADRA1A (0.96) | ADRA1AADRA1DADRA1BADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108066304-B | Tamsulosin orally disintegrating tablet composition with sustained release performance | 深圳万和制药有限公司 | 2022-09-16 | — | — | CN | claimed |
| CN-108066347-B | Orally disintegrating tablet pharmaceutical composition comprising tamsulosin and dutasteride | 深圳万和制药有限公司 | 2021-02-02 | — | — | CN | claimed |
| US-20190133977-A1 | DELAYED RELEASE ORAL TAMSULOSIN HYDROCHLORIDE | ASPEN PARK PHARMACEUTICALS, INC. (US) | 2019-05-09 | — | — | US | claimed |
| CN-109562071-A | delayed release oral tamsulosin hydrochloride | 艾森潘帕克制药股份有限公司 | 2019-04-02 | — | — | CN | claimed |
| EP-3452016-A1 | DELAYED RELEASE ORAL TAMSULOSIN HYDROCHLORIDE | Aspen Park Pharmaceuticals Inc. (US) | 2019-03-13 | — | — | EP | claimed |
| CN-106478467-B | The method for preparing stable tamsulosin hydrochloride | 深圳万和制药有限公司 | 2018-07-13 | — | — | CN | claimed |
| CN-108096220-A | A kind of sustained-release preparation of tamsulosin hydrochloride and preparation method thereof | 苏州中化药品工业有限公司 | 2018-06-01 | — | — | CN | claimed |
| WO-2017192808-A1 | DELAYED RELEASE ORAL TAMSULOSIN HYDROCHLORIDE | ASPEN PARK PHARMACEUTICALS, INC. (US) | 2017-11-09 | — | — | WO | claimed |
| US-20170231974-A1 | Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent | ASTELLAS IRELAND CO., LTD. (IE) | 2017-08-17 | — | — | US | claimed |
| US-20130267557-A1 | Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent | ASTELLAS IRELAND CO., LTD. (IE) | 2013-10-10 | — | — | US | claimed |
| WO-2010051996-A1 | COMBINED USE OF AN ALPHA-ADRENERGIC RECEPTOR ANTAGONIST AND AN ANTI-MUSCARINIC AGENT | ASTELLAS IRELAND CO., LTD. (IE) | 2010-05-14 | — | — | WO | claimed |
| EP-2181707-A1 | Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent | Astellas Ireland Co., Ltd. (IE) | 2010-05-05 | — | — | EP | claimed |
| US-20070161709-A1 | Amorphous tamsulosin hydrochloride | LEK PHARMACEUTICALS D.D. (SI) | 2007-07-12 | — | — | US | claimed |
| EP-1713769-A1 | AMORPHOUS TAMSULOSIN HYDROCHLORIDE | LEK Pharmaceuticals D.D. (SI) | 2006-10-25 | — | — | EP | claimed |
| WO-2005075416-A1 | AMORPHOUS TAMSULOSIN HYDROCHLORIDE | LEK PHARMACEUTICALS D.D. (SI) | 2005-08-18 | — | — | WO | claimed |
| EP-0533297-B1 | Controlled-release pharmaceutical formulations | YAMANOUCHI PHARMA CO LTD (JP) | 1997-11-19 | — | — | EP | claimed |
| EP-0194838-B1 | CONTROLLED-RELEASE PHARMACEUTICAL FORMULATION | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1993-06-09 | — | — | EP | claimed |
| EP-0533297-A1 | Controlled-release pharmaceutical formulations | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1993-03-24 | — | — | EP | claimed |
| US-4868216-A | ANTIADRENERGIC AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1989-09-19 | — | — | US | claimed |
| US-4772475-A | ACRYLIC ACID (CO)POLYMERS, CRYSTALLINE CELLULOSE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-09-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267557-A1 | Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent | ADRB1, ADRB2, ADRB3 | ADRA1A 4/4885ADRA1D 6/4885ADRA1B 5/4885 |
| US-20170231974-A1 | Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent | ADRB1, ADRB2, ADRB3 | ADRA1A 4/4885ADRA1D 6/4885ADRA1B 5/4885 |
| US-20070161709-A1 | Amorphous tamsulosin hydrochloride | TPSB2, ADRA1B, TPSAB1 | ADRA1A 11/4885ADRA1D 9/4885ADRA1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.